From Metabolic Syndrome to Cardiometabolic Risk...

Cardiometabolic Health Congress

October 19–21, 2006 • Marriott Copley Place • Boston, MA

Type 2 Diabetes Dyslipidemia Obesity Hypertension Insulin Resistance Inflammation

Interact with Leading Experts in Cardiometabolic Risk Management!

Christie M. Ballantyne, MD
Baylor College of Medicine

Richard W. Nesto, MD
Harvard Medical School

Jay S. Skyler, MD
University of Miami

Don’t Miss Our Interactive Case Studies, Meet-the-Expert, and Debate Sessions!

ASSOCIATION SUPPORTERS

American Diabetes Association
American Heart Association
ACPM American College of Preventive Medicine
APAC The American Pharmacists Association
The Endocrine Society
ASEPA
ABC Association of Black Cardiologists

This activity is jointly sponsored by Health Science Media, Inc. and Medical Education Collaborative, Inc. (MEC). MEC is a non-profit organization that has been certifying quality educational activities since 1988.

Attend the Most Comprehensive Cardiometabolic Risk Management Event and Earn up to 18.25 CME Credits!

www.cardiometabolichealth.org
Dear Colleague:

Please join us and our distinguished faculty for the 2006 Cardiometabolic Health Congress, taking place October 19–21, 2006, at the Marriott Copley Place in Boston, MA.

The 2006 Cardiometabolic Health Congress will translate the latest clinical data and research into practical and effective approaches to identify and effectively manage your patients at increased cardiometabolic risk.

The goal of the congress is to improve outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.

We are committed to making the 2006 Cardiometabolic Health Congress one of the most productive and influential educational opportunities available to the medical community.

We look forward to seeing you in Boston!

Christie M. Ballantyne, MD
Baylor College of Medicine

Richard W. Nesto, MD
Harvard Medical School

Jay S. Skyler, MD, MACP
University of Miami

Who Should Attend?

Clinicians responsible for the prevention and management of diabetes and cardiovascular disease – with the goal of reducing cardiovascular risk and related cardiometabolic complications

Don’t Miss the Opportunity to Interact with Leading Clinicians from Across the United States!

Albany Medical College, American Diabetes Association, Arkansas Heart Center, Blue Cross Blue Shield of Massachusetts, Baylor College of Medicine, Berkshire Health Systems, Berkshire Visiting Nurse Association, Beverly Hospital Hunt Center, Boston Medical Center, Brigham and Women’s Hospital, Centre Cardiovasculaire de Laval, Children’s Hospital Boston, Children’s Hospital Los Angeles, Harvard Medical School, Clinical Cardiology, Clinic de Prevention de la maladie Vascular el de Lipides, Columbia University College of Physicians and Surgeons, Cumberland Valley Endocrinology, Dartmouth Preventive Medicine, Dow Chemical Company, Duke University Medical Center, East Carolina University, Emory University School of Medicine, Edward Heart Hospital, Endocrinology Consultants of East Tennessee, Fort Wayne Endocrinology, Harvard Medical School, Health Care Partners, Healthy Communities Access Project @ CHP, Heart & Vascular Center, Hilltown Community Health Center, James Madison University, Jefferson Medical College, Joslin Diabetes Center, Kaiser Permanente, Lahey Clinic, Lifestyle Management Institute, Lincoln Medical and Dental Health Center, Massachusetts General Hospital, Mayo Clinic Arizona, Mercer University, Mid-Atlantic Cardiovascular Associates, Milton Hospital, Mount Sinai Heart Clinical Trials Unit, Mount Sinai Hospital, Mount Sinai Medical Center, Mount Sinai School of Medicine, New Mexico Heart Institute, North Country CHC, Nyaack Hospital/Good Samaritan Hospital, Partners HealthCare, PCM, PharmaGenesis, Inc., Prahrbaker Medical LLC, Prairie Cardiovascular Consultants, Range Regional Health Services, Raritan Bay Cardiology Group, Rochester Lifestyle Change, Salazar Medical Group PC, Self Regional Healthcare, Shawnee Mission Medical Center, Southern Jamaica Plain Health Center/Brigham & Women’s Hospital, Southern Nevada Health District, Springfield Diabetes & Endocrinology Center, St. Joseph Healthcare, St. Joseph Hospital, St. Luke’s-Roosevelt Hospital, St. Vincent Health Systems, SUNY Upstate Medical University at Syracuse, NY, The Heart Center, The Miriam Hospital, Tulane University Health Sciences Center, University of Colorado Health Sciences Center, University of Maryland School of Medicine, University of Michigan, University of Miami, University of Texas Health Science Center at San Antonio, VA Hudson Valley Health Care System, Weill-Cornell Medical College, Wellspan Health, West Roxbury Veterans Administration, White-Wilson Medical Center, Wright State University, Yale University School of Medicine
Join the Experts in Cardiometabolic Risk Management!

Chairpersons

Christie M. Ballantyne, MD  
Baylor College of Medicine

Richard W. Nesto, MD  
Harvard Medical School

Jay S. Skyler, MD, MACP  
University of Miami  
Miller School of Medicine

Distinguished Faculty

Louis J. Aronne, MD  
Weill-Cornell Medical College

C. Ronald Kahn, MD  
Joslin Diabetes Center

Jorge Plutzky, MD  
Brigham and Women's Hospital

Christopher P. Cannon, MD  
Brigham and Women's Hospital

Francine R. Kaufman, MD  
Children's Hospital Los Angeles

Daniel J. Rader, MD  
Penn Cardiac Care at  
Presbyterian Medical Center

Jean-Pierre Després, PhD  
Laval Hospital Research Center

David E. Kelley, MD  
University of Pittsburgh  
Medical Center

Paolo Raggi, MD  
Emory University  
School of Medicine

Robert H. Eckel, MD  
University of Colorado at  
Denver Health Sciences Center

William E. Kraus, MD  
Duke University  
Medical Center

Neil B. Ruderman, MD  
Boston Medical Center

Vivian Fonseca, MD  
Tulane University Health Sciences Center

Thomas H. Lee, MD  
Partners HealthCare  
System, Inc.

Frank M. Sacks, MD  
Brigham and Women's Hospital

John P. Foreyt, PhD  
Baylor College of Medicine

Kenneth G. MacDonald, MD  
Brody School of Medicine at  
East Carolina University

Gerald I. Shulman, MD PhD  
Yale School of Medicine

Henry N. Ginsberg, MD  
Columbia University  
College of Physicians  
and Surgeons

Nancy Houston Miller, RN BSN  
Stanford University  
School of Medicine

Scott Urquhart, PA-C  
James Madison University  
Physician Assistant Program

Steven M. Haffner, MD  
University of Texas  
Health Science Center at  
San Antonio

David M. Nathan, MD  
Harvard Medical School

Matthew R. Weir, MD  
University of Maryland  
School of Medicine

Matthew M. Hutter, MD  
Massachusetts General Hospital

Elizabeth O. Ofili, MD MPH  
Morehouse School of Medicine

Stephen D. Wiviott, MD  
Brigham and Women's Hospital

Richard A. Kahn, PhD  
American Diabetes Association

F. Xavier Pi-Sunyer, MD MPH  
St. Luke's-Roosevelt Hospital
Progr
ada Day One – Thursday, October 19, 2006

7:00am - 8:00am  Continental Breakfast

8:00am - 8:15am  OPENING REMARKS  

Jay Skyler, MD

8:15am - 9:00am  KEYNOTE PRESENTATION  

Assessing Global CVD and Type 2 Diabetes Risk: From Metabolic Syndrome to Cardiometabolic Risk 
Jean-Pierre Després, PhD

• Clear the confusion between the conceptual definition of the metabolic syndrome vs. the clinical criteria to identify individuals with the metabolic syndrome
• Review evidence that visceral obesity is, in clinical practice, the most prevalent form of insulin resistant state
• Discuss the need to incorporate metabolic syndrome in global cardiovascular disease risk assessment
• Introduce "hypertriglyceridermic waist" as a useful and simple phenotype defining a subgroup of obese patients with the features of the metabolic syndrome increasing the risk of type 2 diabetes and cardiovascular diseases, such global risk being defined as cardiometabolic risk

9:00am - 9:30am  Biomarkers for Cardiometabolic Risk Assessment in Clinical Practice  

Robert Eckel, MD

• What biomarkers belong to “The Cheap and Easy”?  
• The “Expanding Horizon” of biomarkers: What is reasonable and at least somewhat informative?  
• What are the biomarkers of increasing interest, but not ready for prime time?

9:30am - 10:00am  Inflammation: Etiology and Biomarkers  

Christie Ballantyne, MD

• Review the evidence that inflammation occurs in adipose tissue with obesity
• Appreciate the mechanism by which inflammation in adipose tissue may lead to insulin resistance
• Discuss how inflammation in adipose tissue can accelerate atherosclerotic vascular disease
• Understand that inflammation is a critical link for cardiometabolic risk

10:00am - 10:30am  Exhibit Hall/Morning Break

10:30am - 11:00am  Current and Emerging Therapies for Obesity  

Louis Aronne, MD

• Understand the current research in obesity and how it will impact the future of obesity treatment
• Understand the neuroendocrine aspects of obesity and how this contributes to the difficulty of obese patients to lose and maintain weight
• Understand the mechanism of action and clinical aspects of pharmacologic agents in development to treat obesity

11:00am - 11:30am  Current and Emerging Therapies for Hypertension  

Matthew Weir, MD

• Understand the rationale behind lower blood pressure goals and reduced risk for cardiovascular events
• Understand the results of clinical trials such as HOPE and ALLHAT and how they influence guidelines and decision making in hypertension therapeutics
• Appreciate the need for individualizing blood pressure goals, understanding cardiovascular comorbidity, and the requirement for multiple antihypertensive medications for achievement of blood pressure goals
• Understand the need for lower blood pressure goals in patients with cardiovascular or renal disease, or diabetes mellitus
• Appreciate the need for performing new clinical trials to evaluate optimal combinations of medications to facilitate lower blood pressure goals and reduce cardiovascular events

“It is critical that physicians and health care providers understand how to identify patients with obesity who have increased risk for the development of diabetes and cardiovascular disease and how to manage the cardiometabolic risks associated with obesity.”  
Christie Ballantyne, MD
CLINICAL TRIALS UPDATE CONTINUED

11:30am - 12:00pm
Current and Emerging Therapies for Dyslipidemia
Christopher Cannon, MD
• Become familiar with new data on intensive statin therapy
• Understand current data on the mechanism of action of statin therapy
• Learn of new non-statin therapies, including fibrates and ezetimibe

12:00pm - 12:30pm
Current and Emerging Therapies for Type 2 Diabetes
David Nathan, MD
• Understand the magnitude and causes of the type 2 diabetes epidemic
• Recognize the demonstrated benefits of intensive management of glycemia, demonstrated in clinical trials, as it relates to long-term complications
• Understand the relative advantages and disadvantages of the currently available diabetes interventions
• Learn the recently recommended algorithm for the metabolic management of type 2 diabetes

12:30pm - 1:45pm
LUNCH SYMPOSIUM
Cardiometabolic Risk Reduction: Targeting Abdominal Adiposity and the Endocannabinoid System
Louis Aronne, MD; Robert Eckel, MD; Richard Nesto, MD

1:45pm - 2:15pm
Glitazones: What Is Their Role in Cardiometabolic Risk Management?
Jorge Plutzky, MD
• Understand PPARs and their mechanism of action and use as a drug target
• Review the existing basic science and clinical data that provides a rationale for considering PPAR-gamma activation by thiazolidinediones as a treatment for cardiometabolic risk
• Consider the limitations in thiazolidinediones as a treatment for metabolic syndrome
• Discuss future options in PPAR targeting for the treatment of cardiometabolic risk

2:15pm - 3:15pm
DISCUSSION & DEBATE
LDL, Triglycerides, and HDL: Which Risk Factors Are Most Important?
Moderator: Christie Ballantyne, MD
Panelists: Stephen Wiviott, MD; Frank Sacks, MD; Christopher Cannon, MD

3:15pm - 3:45pm
Prevention, Treatment, and Control of Type 2 Diabetes
Vivian Fonseca, MD
• Understand the impact of insulin resistance on the development and progression of type 2 diabetes and cardiovascular disease
• Evaluate clinical trial data to suggest that it is possible to prevent diabetes in patients with the metabolic syndrome using a variety of medications in addition to lifestyle change
• Examine the impact of insulin sensitizer therapy on the risk of cardiovascular disease in patients with pre-diabetes and the metabolic syndrome

3:45pm - 4:15pm
The Patient with Diabetes and Heart Disease: Strategies to Prevent a Second Coronary Event
Richard Nesto, MD
• Identification of cardiometabolic risk factors responsible for coronary events in the patients considered to be "adequately" managed according to current guidelines
• Overweight and obesity as a target "organ" for modification beyond traditional risk factors for cardiovascular risk

4:15pm - 4:45pm
CLOSING REMARKS
Jay Skyler, MD

5:00pm - 6:30pm
WELCOME RECEPTION IN EXHIBIT HALL
sponsored by sanofi aventis

“How low should you go, and what drugs should you use? Vexing questions which are particularly important in patients at increased cardiometabolic risk with elevated blood pressure. Perhaps a more interesting question is whether we should prevent blood pressure elevation in these patients who are not yet hypertensive.”
Matthew Weir, MD
Inhibiting RAAS at the Point of Activation: A Novel Antihypertensive Therapeutic Option

Christie Ballantyne, MD

Insulin Resistance, Obesity, and Type 2 Diabetes
C. Ronald Kahn, MD
- Review how insulin works and how insulin resistance occurs
- Understand how insulin resistance in different tissues can contribute different parts of the metabolic syndrome of diabetes
- Describe the unique role of insulin resistance in fat

How to Assess Quality in Clinical Practice
Thomas Lee, MD
- Describe market forces that are promoting the use and public reporting of measures for quality of cardiovascular care
- Describe the major quality measures for physician care of patients at increased cardiometabolic risk
- Describe the most important tools and systems that can be used to capture data and improve quality of care for patients at increased cardiometabolic risk

Do Current Guidelines Accurately Identify Cardiometabolic Risk?
Moderator: Richard Nesto, MD
Panelists: Christie Ballantyne, MD; Robert Eckel, MD; Richard Kahn, PhD; F. Xavier Pi-Sunyer, MD

Visceral Fat vs. Liver Fat vs. Muscle Fat: Where Does the Problem Arise?
Moderator: Jay Skyler, MD
Panelists: Jean-Pierre Després, PhD; Gerald Shulman, MD; David Kelley, MD

The Role of DPP-IV Inhibition in Achieving Glycemic Control

Cardiometabolic Risk in Children: How Should It Be Defined, Who Does It Affect, and What Should We Do?
Francine Kaufman, MD
- Understand how cardiometabolic risk is defined in children
- Be familiar with cardiometabolic risk factors in children
- Understand treatment/intervention strategies

Cardiometabolic Risk in High-Risk Populations
John Foreyt, PhD
- Define the components of cardiometabolic risk in high-risk populations
- Evaluate current therapies for the management of cardiometabolic risk in high-risk populations
- Discuss successful lifestyle modification programs for high-risk patients

Emerging Technologies: Assessment of Screening Tools and Their Role in Clinical Practice
Moderator: Christie Ballantyne, MD
Presenters: Richard Nesto, MD; Paolo Raggi, MD
- Assess current modalities to screen for subclinical CAD in diabetic patients
- Identify appropriate patients for screening and risk quantification for CHD
- Understand the utility of modern imaging technologies to better define risk in the metabolic syndrome
- Appreciate the appropriate indications for imaging as a tool to assess cardiovascular risk

“The biggest health problem facing the world today is from the combined impact of obesity, diabetes, and cardiovascular disease. In previous centuries the major scourges were from acute infectious diseases. Today the impact is from this compilation of chronic diseases.”

Jay Skyler, MD
2:15pm - 2:45pm  CONCURRENT SESSIONS CONTINUED

**Exercise, AMPK, and the Treatment and Prevention of the Metabolic Syndrome**

*Neil Ruderman, MD*

- Understand the biochemistry of AMP-activated protein kinase
- Become aware of the relationship between physical activity and the prevalence of type 2 diabetes, premature cardiovascular disease, and other disorders associated with the metabolic syndrome
- Become familiar with the AMPK/malonyl CoA fuel sensing and signaling mechanism and how it is affected by exercise
- Review the evidence that dysregulation of AMPK/malonyl CoA underlies a wide variety of disorders associated with insulin resistance and altered lipid metabolism in rodents
- Review the evidence that AMPK and malonyl CoA are targets for treating the metabolic syndrome

2:45pm - 3:15pm  **Fat vs. Carbohydrates vs. Protein: What Type of Diet Should You Recommend to Your Patients?**

*Frank Sacks, MD*

- Learn how dietary fats, carbohydrates, and protein affect differently LDL cholesterol, the primary lipid target
- Learn how dietary fats, carbohydrates, and protein affect triglycerides and HDL cholesterol, the independent lipid risk factors of the metabolic syndrome
- Learn what diet types are most effective for weight loss
- Combine objectives 1–3 to formulate the most effective dietary approaches to reduce cardiovascular risk

3:15pm - 3:45pm  **Afternoon Break/Exhibit Hall**

3:45pm - 4:45pm  **Strategies for Improving Patient Compliance to Diet, Lifestyle, and Medical Therapies**

*Moderator: F. Xavier Pi-Sunyer, MD  Presenters: William Kraus, MD; Nancy Miller, RN BSN*

- Understand the importance of using a cognitive model in the clinic setting to underlie counseling about lifestyle interventions
- Understand how a clinic environment supporting lifestyle change can be incorporated into a clinic model
- Understand the importance of encouraging exercise as an effective therapy for cardiometabolic risk
- Identify strategies to attain dietary change and physical activity compliance

3:45pm - 4:45pm  **Bariatric Surgery: Patient Selection, Procedure Options, and Long-Term Outcomes**

*Moderator: Christie Ballantyne, MD  Presenters: Kenneth MacDonald, MD; Matthew Hutter, MD*

- Understand which patients might benefit from weight-loss surgery
- Review the criteria and the processes involved in patient selection
- Understand the options available for weight-loss surgery, including the anatomy and physiology, and procedure-related specifics
- Evaluate the short- and long-term outcomes for the different weight-loss procedures, including complications and mortality, weight-loss over time, and reduction in weight-related comorbid illnesses

4:45pm - 5:15pm  **CLOSING SESSION**

**Strategies for the Prevention of Heart Disease in Patients with Type 2 Diabetes**

*Jay Skyler, MD*

- Summarize the various ways in which cardiovascular disease evolves in patients with type 2 diabetes
- Develop intervention strategies to reduce cardiovascular disease risk in patients with type 2 diabetes

5:15pm  **CLOSING REMARKS**

*Richard Nesto, MD*

---

**Attend Our Comprehensive Cardiometabolic Risk Management Review and Get Answers:**

- What is the impact of obesity, insulin resistance, and type 2 diabetes on cardiovascular risk?
- The patient with type 2 diabetes and heart disease: How do you prevent a second coronary event?
- Which risk factors should you be targeting: LDL, HDL, triglycerides?
- Fat vs. carbohydrates vs. protein: What diet should you recommend?
- How do you identify appropriate patient candidates for bariatric surgery?

---

“The 2006 Cardiometabolic Health Congress is an extremely important initiative. Cardiometabolic risk is an epidemic which Americans have long overlooked and underestimated as far as inherent cardiovascular risk is concerned.”

---

www.cardiometabolichealth.org
7:00am - 8:15am  Continental Breakfast

8:30am - 9:30am  CONCURRENT SESSIONS

MEET-THE-EXPERT SESSION

Disease Prevention: Establishing and Integrating Necessary Lifestyle Changes
Scott Urquhart, PA-C; William Kraus, MD

- Know the risk factors and counterproductive lifestyles leading to obesity and the subsequent medical conditions associated with it
- Gain insight into the physical and emotional difficulties that obese patients face on a daily basis in order to enhance your therapeutic approach
- Create inquisitive interviewing skills, treatment options, and follow-up plans
- Implement positive lifestyle changes, articulate relapse prevention, and set obtainable goals to promote successful weight loss and maintenance

8:30am - 9:30am  MEET-THE-EXPERT SESSION

Metabolic Syndrome as a Predictor of Type 2 Diabetes
Steven Haffner, MD

- Learn about definitions of the metabolic syndrome
- Explore the controversies about the metabolic syndrome deriving from the ADA position statement in 2005
- Learn about the risk of the metabolic syndrome for patients with cardiovascular disease and type 2 diabetes

9:30am - 10:00am  Exhibit Hall/Morning Break

10:00am - 11:00am  MEET-THE-EXPERT SESSION

Optimizing the Care of the Cardiometabolic Patient in the Hospital and Post-Hospitalization Setting
Richard Nesto, MD

- Evaluate the role of hyperglycemia in hospitalized patients as a factor responsible for morbidity and mortality
- Learn about the importance of insulin as an agent to minimize hyperglycemia in this setting
- Critically review the data related to GIK and other regimens to treat metabolic risk in hospitalized patients

10:00am - 11:00am  CHALLENGING CASE STUDIES SESSION

Challenging Case Studies in Metabolic Syndrome
F. Xavier Pi-Sunyer, MD

11:00am - 12:00pm  CHALLENGING CASE STUDIES SESSION

Challenging Case Studies in Bariatric Surgery Patient Selection
Matthew Hutter, MD

11:00am - 12:00pm  CHALLENGING CASE STUDIES SESSION

Cardiometabolic Risk Management in High-Risk Populations
John Foreyt, PhD

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and HealthScience Media, Inc. (HSM). MEC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Collaborative designates this educational activity for a maximum of 18.25 category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

ANCC and dietitian credits offered. For more information, please visit www.cardiometabolichealth.org.

“Metabolic factors represent the major component of cardiovascular risk. Such factors are worsening at an alarming rate in the US population. The good news is that they are amenable through lifestyle interventions. A key component of the 2006 Cardiometabolic Health Congress will aid the clinician in implementing effective lifestyle changes in their patients.”

William Kraus, MD
Purpose Statement
Patients presenting with multiple cardiometabolic risk factors (including insulin resistance, dyslipidemia, obesity, hypertension, microalbuminuria, inflammation, and oxidative stress) have triple the risk of experiencing a myocardial infarction and/or stroke and double the risk of mortality from these conditions. In addition, their risk for developing type 2 diabetes, if not already present, is fivefold.

The 2006 Cardiometabolic Health Congress will provide practical treatment approaches and effective strategies to identify and manage patients at increased cardiometabolic risk – with the goal of improving treatment outcomes as well as the prevention of diabetes and cardiovascular disease.

Learning Objectives
• Assess the clinical impact of early identification and management of cardiometabolic risk
• Evaluate and integrate current and emerging therapies and treatment regimens into clinical practice
• Determine the most advantageous clinical and therapeutic strategies for reducing cardiovascular risk based on patient comorbidities and risk factors
• Integrate successful programs into clinical practice that promote better patient compliance to medical therapies and lifestyle modifications

Hotel and Travel Information
Location: Boston Marriott Copley Place
110 Huntington Ave.
Boston, MA 02116
Tel: 617.236.5800
Fax: 617.236.5885
www.copleymarriott.com

Special Group Room Rate: $265 (single or double occupancy)
To book your hotel room with the 2006 Cardiometabolic Health Congress room block, please utilize the link www.stayatmarriott.com/CHC/ or call 617.236.5800 and reference "2006 Cardiometabolic Health Congress." You must reserve your room before September 27, 2006, to receive the discounted room rate.
Reserve early, as space is limited.

Should you need the assistance of a travel agent for arranging your travel, please contact David O'Brien at The Travel Collaborative.
Tel: 800.370.7400 x37
Email: reid@tvcoll.com

Special Discount Offer for 2006 Cardiometabolic Health Congress Attendees!
Attend The Obesity Society's Annual Scientific Meeting:
Saturday only: $195 / Saturday – Tuesday $495
For more information visit www.naaso.org.

"The 2006 Cardiometabolic Health Congress will be one of the first to fully evaluate cardiometabolic health from a definition of cardiac risk to the widest variety of treatment modalities. Field experts will come together and help fully define cardiometabolic risk within the context of patient care both in the here and now."
Richard Nesto, MD

www.cardiometabolichealth.org
The 2006 Cardiometabolic Health Congress gratefully acknowledges the education grant support and sponsorship provided by the following organizations.

**Foundation Supporter**

**Platinum Supporter**

**Silver Supporters**

**Bronze Supporters**

**Additional Grant Support**

**Sponsors**

---

**Educational Support, Sponsorship, and Exhibit Opportunities**

For More Information Call: 877.571.4700 or E-mail: info@cardiometabolichealth.org

**Association Member Discount!**

Current members of associations supporting the 2006 Cardiometabolic Health Congress receive a $100 discount.

<table>
<thead>
<tr>
<th>Association</th>
<th>Association</th>
<th>Association</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Endocrine Society</td>
<td>American Society of Preventive Cardiology</td>
<td>Preventive Cardiology Nursing Association</td>
</tr>
<tr>
<td>Association of Black Cardiologists</td>
<td>American Society of Endocrine PAs</td>
<td>American Heart Association</td>
</tr>
<tr>
<td>Association of PAs in Cardiology</td>
<td>Partnership for Prevention</td>
<td>American Diabetes Association</td>
</tr>
<tr>
<td>American Society of Hypertension</td>
<td>American College of Preventive Medicine</td>
<td>American Medical Women's Association</td>
</tr>
<tr>
<td>Society of Atherosclerosis Imaging and Prevention</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

October 19–21, 2006 • Marriott Copley Place • Boston, MA
EXPLORING A NEW FRONTIER FOR CARDIOMETABOLIC RISK REDUCTION

METABOLIC SYNDROME: THE CLUSTER OF CARDIOMETABOLIC RISK FACTORS

- Decreased HDL-C
- Elevated blood pressure
- Elevated triglycerides
- Elevated fasting glucose
- Increased waist circumference (excess adipose tissue)

ADIPOSE TISSUE IS A METABOLICALLY ACTIVE ENDOCRINE ORGAN

- Associated with abnormal endocrine function—impacts secretions of bioactive substances that help regulate lipid and glucose metabolism
- May lead to development of cardiometabolic risk factors like dyslipidemia, elevated blood glucose, and insulin resistance

THE ENDOCANNABINOID SYSTEM (ECS) IMPACTS METABOLIC FUNCTIONS

- ECS is a newly discovered physiologic system
- Consists of signaling molecules and their receptors, including the cannabinoid receptors [CB1 and CB2]

CB	extsubscript{2} RECEPTORS MAY IMPACT LIPID LEVELS AND INSULIN SENSITIVITY

- Located throughout the body, including the brain, liver, muscle, and adipose tissue
- Overactivity in adipose tissue is associated with decreases in adiponectin, which may be linked to dyslipidemia, insulin resistance, and intra-abdominal adiposity
- At the center of a cascade of events with potential impact on cardiometabolic risk

References

Brought to you by sanofi aventis
Registration Form

Online: www.cardiometabolichealth.org
Call: Jessica at 877.571.4700
Fax Registration Form: 866.218.9168
Mail Registration Form with Payment to:
2006 Cardiometabolic Health Congress
c/o HealthScience Media, Inc.
75 Lincoln Highway, Suite 201, Iselin, NJ 08830

<table>
<thead>
<tr>
<th>Prefix</th>
<th>First Name</th>
<th>Last Name</th>
<th>Degree(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Title

Affiliation

Address 1

Address 2

<table>
<thead>
<tr>
<th>City</th>
<th>State</th>
<th>Zip Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Tel

Fax

Email

Guest Name (if you are purchasing a guest pass):

Please indicate your specialty (check one):
- Cardiology
- Endocrinology
- Internal Medicine
- Nephrology
- Primary Care
- Industry
- Other

Current members of our association alliances receive a $100 discount off the registration price.
Indicate which association you are a member of below:

- The Endocrine Society
- Association of Black Cardiologists
- Association of PAs in Cardiology
- American Society of Hypertension
- Society of Atherosclerotic Imaging and Prevention
- American Society of Preventive Cardiology
- American Society of Endocrine PAs
- Partnership for Prevention
- American College of Preventive Medicine
- Preventive Cardiology Nursing Association
- American Heart Association
- American Diabetes Association
- American Medical Women's Association

Total Amount Due:

<table>
<thead>
<tr>
<th>Method of Payment</th>
<th>Check</th>
<th>Credit Card</th>
<th>Visa</th>
<th>MasterCard</th>
<th>American Express</th>
<th>Discover</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Account Number

Expiration Date

Cardholder Name

Cardholder Signature

Cancellation Policy: Cancellations must be made in writing via fax or email to 866.218.9168/cancellation@cardiometabolichealth.org. Refunds, less a $100 service fee, will be given if written cancellation is received no later than September 28, 2006. No refunds will be given after September 28, 2006. You may send a substitute, even at the last minute. To send a substitute, please call 877.571.4700 or email request to registration@cardiometabolichealth.org.